CA2845806C - Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof - Google Patents
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof Download PDFInfo
- Publication number
- CA2845806C CA2845806C CA2845806A CA2845806A CA2845806C CA 2845806 C CA2845806 C CA 2845806C CA 2845806 A CA2845806 A CA 2845806A CA 2845806 A CA2845806 A CA 2845806A CA 2845806 C CA2845806 C CA 2845806C
- Authority
- CA
- Canada
- Prior art keywords
- bendamustine
- compound
- carcinoma
- hdac inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/051470 WO2013039488A1 (en) | 2011-09-13 | 2011-09-13 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2845806A1 CA2845806A1 (en) | 2013-03-21 |
| CA2845806C true CA2845806C (en) | 2019-06-11 |
Family
ID=47883567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2845806A Active CA2845806C (en) | 2011-09-13 | 2011-09-13 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9492423B2 (enExample) |
| EP (1) | EP2755648B1 (enExample) |
| JP (1) | JP6330118B2 (enExample) |
| KR (1) | KR101892788B1 (enExample) |
| CN (1) | CN103917231B (enExample) |
| AU (1) | AU2011376953B2 (enExample) |
| CA (1) | CA2845806C (enExample) |
| ES (1) | ES2627820T3 (enExample) |
| MX (1) | MX365393B (enExample) |
| NZ (1) | NZ621221A (enExample) |
| RU (1) | RU2609833C2 (enExample) |
| SG (1) | SG2014014419A (enExample) |
| UA (1) | UA110853C2 (enExample) |
| WO (1) | WO2013039488A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
| NZ621221A (en) | 2011-09-13 | 2016-07-29 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| US9937174B2 (en) * | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| WO2016205695A1 (en) * | 2015-06-19 | 2016-12-22 | Faller Douglas V | Methods and compositions for treating herpesvirus induced conditions |
| RU2760304C2 (ru) | 2016-04-08 | 2021-11-23 | Серено Сайентифик Аб | Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение |
| US20200179381A1 (en) * | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| KR20220100077A (ko) | 2016-04-21 | 2022-07-14 | 발큐리아 에이비 | 암의 예비치료용 조성물 및 방법 |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| GB201706544D0 (en) * | 2017-04-25 | 2017-06-07 | Plasticell Ltd | Method |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| NZ749727A (en) * | 2018-01-05 | 2020-07-31 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
| WO2020128913A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
| MX2021014639A (es) | 2019-05-31 | 2022-04-06 | Viracta Subsidiary Inc | Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa. |
| CN116018133A (zh) | 2020-06-26 | 2023-04-25 | 博士医疗爱尔兰有限公司 | 靶向释放利福昔明组合物 |
| WO2022159852A1 (en) * | 2021-01-25 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Methods and compositions for treating adenoid cystic carcinoma |
| WO2024086688A1 (en) * | 2022-10-21 | 2024-04-25 | Viracta Subsidiary, Inc. | Dosing methods for hdac inhibitor compounds |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3126375A (en) | 1964-03-24 | Chioacyl | ||
| US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
| US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
| US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
| US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
| BE794063A (fr) | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | Anti-inflammatoires pour compositions cosmetiques |
| SE378110B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
| SE378109B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3775656A (en) | 1972-05-22 | 1973-11-27 | Aviat Inc | Platform stabilization system |
| CH581818A5 (enExample) | 1973-02-27 | 1976-11-15 | Cierva Juan J De | |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| EP0084236A3 (en) | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
| US4498038A (en) | 1983-02-15 | 1985-02-05 | Malueg Richard M | Stabilization system for soft-mounted platform |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| DE3684446D1 (de) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | Arzneimittel mit verzoegerter stossweiser freisetzung. |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| WO1989003819A1 (fr) | 1987-10-20 | 1989-05-05 | Otsuka Pharmaceutical Co., Ltd. | Derives d'acide phenylcarboxylique |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| JPH03215470A (ja) | 1990-01-22 | 1991-09-20 | Suntory Ltd | プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤 |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| DE4124345A1 (de) | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel |
| AU661080B2 (en) | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| KR100291362B1 (ko) | 1992-10-16 | 2001-09-17 | 니뽄 신야쿠 가부시키가이샤 | 왁스매트릭스의제법 |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
| US5448938A (en) | 1993-10-18 | 1995-09-12 | Guardian Technologies International, Inc. | Removable ballistic resistant armor seat cover and floor mat |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6718130B2 (en) | 1999-05-28 | 2004-04-06 | David E. Grober | Stabilized camera and marker buoy for media coverage of aquatic events |
| JP2003500772A (ja) | 1999-05-28 | 2003-01-07 | グロバー、デイビッド、イー | 自主的なセルフレベリング自動修正式安定台 |
| AU6767300A (en) | 1999-08-10 | 2001-03-05 | Pangene Corporation | Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
| MXPA03001771A (es) | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| EP1358353B1 (en) | 2000-12-28 | 2007-06-20 | Epidauros Biotechnologie AG | Identification of genetic determinants of polymorphic cyp3a5 expression |
| MXPA01013172A (es) | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| SI1404304T1 (sl) | 2001-06-28 | 2009-10-31 | Ucb Farchim Sa Z I Planchy | Tableta, obsegajoča cetirizin in psevdoefedrin |
| US7247426B2 (en) | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| DK1426054T3 (da) | 2001-08-21 | 2011-12-12 | Astellas Pharma Inc | Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030166026A1 (en) | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
| JP2005516626A (ja) | 2002-02-04 | 2005-06-09 | エピダウロス バイオテクノロジー アーゲー | Ｔｐｍｔのヒト遺伝子における多型ならびに診断的適用および治療的適用におけるその使用方法 |
| JPWO2003070691A1 (ja) | 2002-02-21 | 2005-06-09 | 財団法人大阪産業振興機構 | Ｎ−ヒドロキシカルボキサミド誘導体 |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| JP2005539001A (ja) | 2002-08-02 | 2005-12-22 | アージェンタ・ディスカバリー・リミテッド | ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸 |
| EP1400806A1 (en) | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
| US6769347B1 (en) | 2002-11-26 | 2004-08-03 | Recon/Optical, Inc. | Dual elevation weapon station and method of use |
| EP1595952A4 (en) | 2003-02-19 | 2008-05-21 | Astellas Pharma Inc | METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| PL1611088T3 (pl) | 2003-04-07 | 2009-11-30 | Pharmacyclics Inc | Hydroksamiany jako środki terapeutyczne |
| ZA200507751B (en) * | 2003-04-07 | 2007-01-31 | Axys Pharm Inc | Novel hydroxamates as therapeutic agents |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| CA2540108A1 (en) | 2003-09-25 | 2005-04-07 | Astellas Pharma Inc. | Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| WO2005043161A2 (en) | 2003-11-04 | 2005-05-12 | Roche Diagnostics Gmbh | Method for distinguishing leukemia subtypes |
| EP1694866A4 (en) | 2003-12-12 | 2007-12-26 | Bayer Pharmaceuticals Corp | GENE EXPRESSION PROFILES AND METHOD OF USE |
| US8019552B2 (en) | 2004-03-05 | 2011-09-13 | The Netherlands Cancer Institute | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| US7368476B2 (en) | 2004-04-07 | 2008-05-06 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
| DE602004014723D1 (de) | 2004-04-30 | 2008-08-14 | Desitin Arzneimittel Gmbh | Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung |
| BRPI0511065A (pt) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
| AU2005267756A1 (en) | 2004-07-30 | 2006-02-09 | Rosetta Inpharmatics Llc | Prognosis of breast cancer patients |
| WO2006042035A2 (en) | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
| CN101933923A (zh) | 2004-11-05 | 2011-01-05 | 赛福伦公司 | 癌症治疗 |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2006101454A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Benzothiophene derivatives: preparation and pharmaceutical applications |
| WO2007109178A2 (en) | 2006-03-16 | 2007-09-27 | Pharmacyclics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| US20090312284A1 (en) | 2006-09-15 | 2009-12-17 | Janine Arts | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
| PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
| EA201201640A1 (ru) | 2007-01-30 | 2013-09-30 | Фармасайкликс, Инк. | Способы определения устойчивости рака к ингибиторам гистондеацетилазы |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| UY34295A (es) | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| NZ621221A (en) | 2011-09-13 | 2016-07-29 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| US9421208B2 (en) | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
-
2011
- 2011-09-13 NZ NZ621221A patent/NZ621221A/en not_active IP Right Cessation
- 2011-09-13 MX MX2014002942A patent/MX365393B/es active IP Right Grant
- 2011-09-13 US US14/344,314 patent/US9492423B2/en active Active
- 2011-09-13 ES ES11872389.9T patent/ES2627820T3/es active Active
- 2011-09-13 CN CN201180074826.7A patent/CN103917231B/zh active Active
- 2011-09-13 EP EP11872389.9A patent/EP2755648B1/en active Active
- 2011-09-13 WO PCT/US2011/051470 patent/WO2013039488A1/en not_active Ceased
- 2011-09-13 JP JP2014530636A patent/JP6330118B2/ja not_active Expired - Fee Related
- 2011-09-13 RU RU2014111069A patent/RU2609833C2/ru not_active IP Right Cessation
- 2011-09-13 KR KR1020147007117A patent/KR101892788B1/ko not_active Expired - Fee Related
- 2011-09-13 UA UAA201402905A patent/UA110853C2/uk unknown
- 2011-09-13 SG SG2014014419A patent/SG2014014419A/en unknown
- 2011-09-13 CA CA2845806A patent/CA2845806C/en active Active
- 2011-09-13 AU AU2011376953A patent/AU2011376953B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014002942A (es) | 2014-09-15 |
| JP6330118B2 (ja) | 2018-05-30 |
| HK1200095A1 (en) | 2015-07-31 |
| NZ621221A (en) | 2016-07-29 |
| AU2011376953B2 (en) | 2017-08-24 |
| ES2627820T3 (es) | 2017-07-31 |
| KR20140073503A (ko) | 2014-06-16 |
| KR101892788B1 (ko) | 2018-08-28 |
| MX365393B (es) | 2019-05-31 |
| UA110853C2 (uk) | 2016-02-25 |
| CN103917231A (zh) | 2014-07-09 |
| JP2014526503A (ja) | 2014-10-06 |
| US9492423B2 (en) | 2016-11-15 |
| CA2845806A1 (en) | 2013-03-21 |
| US20140341989A1 (en) | 2014-11-20 |
| EP2755648A4 (en) | 2015-03-11 |
| AU2011376953A1 (en) | 2014-03-06 |
| EP2755648B1 (en) | 2017-03-08 |
| CN103917231B (zh) | 2016-09-28 |
| RU2609833C2 (ru) | 2017-02-06 |
| SG2014014419A (en) | 2014-07-30 |
| EP2755648A1 (en) | 2014-07-23 |
| WO2013039488A1 (en) | 2013-03-21 |
| RU2014111069A (ru) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011376953B2 (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | |
| US10105552B2 (en) | Formulations of histone deacetylase inhibitor and uses thereof | |
| ES3016532T3 (en) | Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof | |
| US20150335609A1 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| US20140235559A1 (en) | Anti-cancer pharmaceutical composition | |
| BRPI0716436B1 (pt) | sistema de liberação controlada e método para fabricação do mesmo | |
| CN104220068A (zh) | 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 | |
| CN105120845A (zh) | 药物组合药物 | |
| WO2018108157A1 (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| NO20101468L (no) | Sammensetning for setespesifikk levering av imatinib og fremgangsmater for anvendelse | |
| CN105311635A (zh) | 可调控释放度的高载药量的医药组合物及其制备方法 | |
| CN117693333A (zh) | 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用 | |
| HK1200095B (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | |
| CN107213138B (zh) | 定时释放药物治疗高血压的方法和药物组合物 | |
| KR101072600B1 (ko) | 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160705 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250131 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250131 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250131 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251215 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260427 |